U.S. Machinery Stock News

NasdaqGS:PHAT
NasdaqGS:PHATPharmaceuticals

Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility

What recent performance says about Phathom Pharmaceuticals Without a single clear news catalyst, Phathom Pharmaceuticals (PHAT) has still drawn attention after a recent month of modest gains, a stronger move over the past 3 months, and a sharply positive 1 year total return. Those returns sit against a value score of 4 and a share price of about $15.02 at the last close. This has prompted some investors to compare that recent performance with the company’s current fundamentals. See our latest...
NasdaqGS:SBLK
NasdaqGS:SBLKShipping

Is It Too Late To Consider Star Bulk Carriers (SBLK) After Strong Multi‑Year Returns?

This article is for readers wondering whether Star Bulk Carriers still offers value at today’s price or whether most of the opportunity is already reflected in the share price, and is aimed at helping you frame that question clearly. The stock closed at US$19.64, with returns of 1.4% over 7 days, 0.9% over 30 days, 1.4% year to date and 31.0% over the past year, plus 16.3% over 3 years and 199.1% over 5 years. These figures can shape how investors think about both upside and risk...
NYSE:KAI
NYSE:KAIMachinery

Why Kadant (KAI) Is Up 11.5% After Trump’s US$1.5 Trillion Defense Budget Proposal

Kadant recently benefited from a sector-wide rally in industrial names after President Trump called for a proposed US$1.50 trillion defense budget for 2027, prompting investors to reassess companies connected to industrial and defense supply chains. The market’s reaction suggests that while the defense-spending proposal does not fundamentally alter Kadant’s core equipment and aftermarket businesses, it has reinforced investor attention on its exposure to broader industrial investment...
NasdaqCM:IMNM
NasdaqCM:IMNMBiotechs

Assessing Immunome (IMNM) Valuation After Phase 3 Success And Upcoming J.P. Morgan Conference Presentation

Immunome (IMNM) is back in focus after reporting successful Phase 3 data for its lead drug candidate, varegacestat, as well as plans to present at the upcoming J.P. Morgan Healthcare Conference, drawing fresh attention to the stock. See our latest analysis for Immunome. That backdrop helps explain why Immunome’s share price, now at $21.07, has seen a 90 day share price return of 51.36%, while the 1 year total shareholder return sits at 98.77%, suggesting momentum has been building around the...
NYSE:GRND
NYSE:GRNDInteractive Media and Services

Should Grindr’s (GRND) New Marketing and Global Affairs Chiefs Reframe Its Long‑Term Brand Risk Profile?

Grindr Inc. recently elevated Tristan Pineiro to Chief Marketing Officer and Zac Katz to Chief Legal Officer, General Counsel, and Head of Global Affairs, formalizing leadership over brand, advertising accessibility, legal, privacy, government affairs, and social impact initiatives. The appointments consolidate oversight of Grindr’s Global Gayborhood branding and Grindr for Equality advocacy under executives already shaping marketing-led growth, AI-related governance, and global LGBTQ+...
NasdaqGS:EVCM
NasdaqGS:EVCMSoftware

How Mixed Guidance, AI Deal, and Buybacks At EverCommerce (EVCM) Have Changed Its Investment Story

In recent days, EverCommerce reported quarterly results that missed revenue expectations and led management to lower full-year guidance, even as the company achieved profitability and outperformed on adjusted EBITDA, while President Matthew Feierstein continued his pattern of selling 25,000 shares in open-market transactions. At the same time, EverCommerce acquired AI platform ZyraTalk to bolster its SaaS capabilities and expanded its share repurchase authorization by US$50.00 million,...